CAR-T Cell Therapy Clinical Trial for:

  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (Scleroderma)
    • See below for information on our standard-of-care autologous stem cell transplants for systemic sclerosis
  • Idiopathic Inflammatory Myopathies (Dermatomyositis, Immune-mediated Necrotizing Myopathy, and Anti-Synthetase Syndrome)

CBCI is a Foundation for the Accreditation of Cellular Therapies (FACT) accredited center for CAR-T cell therapy. We are offering CAR-T Therapy to eligible SLE, scleroderma and idiopathic inflammatory myopathies (IIM) patients as part of a clinical trial.

What is CAR-T Cell Therapy?

CAR-T Cell Therapy for SLE, Scleroderma, and IIM at CBCI

CAR-T cell therapy is widely available for patients with various blood cancers and is now being studied as treatment for patients with autoimmune diseases. CBCI is a participating site in a clinical trial sponsored by Bristol Myers Squibb to study CAR-T therapy for SLE, Scleroderma, and IIM. These studies are using CAR-T cells to target cells that are major proponents in autoimmune diseases such as SLE, Scleroderma, and IIM. The aim of these studies is to assess the tolerability of the treatment as well as its efficacy.

See the early data supporting the use of CAR-T therapy for lupus.

If you are interested in being screened for AHSCT for systemic sclerosis at CBCI, please contact:

Email Ben Burtness
Phone Number: (303) 981-2305


Autologous Hematopoietic Stem Cell Transplant for Systemic Sclerosis

CBCI is a Foundation for the Accreditation of Cellular Therapies (FACT) accredited center for stem cell transplantation. Dr. Richard Nash and his team have over 20 years of experience with Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for autoimmune diseases. We offer AHSCT to appropriate scleroderma patients.

What is AHSCT?

Check out our AHSCT information page (also called a “Blood and Marrow Transplant”) to learn more.

Standard of Care AHSCT for Scleroderma at CBCI

Our center is offering AHSCT as a standard treatment option for patients with scleroderma. We have participated in multiple studies which have shown that this is a safe and effective treatment option for appropriate patients. A phase 2 study of systemic sclerosis published in Blood 2007 showed a significant decrease in skin fibrosis after stem cell transplants. A phase 3 clinical trial published in the New England Journal of Medicine showed that myeloablative (high intensity) stem cell transplant was a durable, more effective treatment than cyclophosphamide therapy.

See below resources for published articles on Scleroderma and AHSCT:

If you are interested in being screened for AHSCT for systemic sclerosis at CBCI, please contact:

Email Cat Booher
Phone number: (303) 577-6480